This site uses cookies. Some of these cookies are essential to the operation of the site, while others help to improve your experience by providing insights into how the site is being used. For more information, please see the ProZ.com privacy policy.
Cookie settings
Asked
Open questions
Answered
Asked | Open questions | Answered
Date Pair Term Level Status Answers (undeclined) Gloss
May 28 '17 eng>rus comprises HEK293 cell glycosylation pro just_closed 0 no
May 28 '17 eng>rus extracted from a human donor subject pro closed 1 no
May 27 '17 eng>rus fragment competes with pro closed 1 no
May 27 '17 eng>rus for specific antibody deposit number pro closed 1 no
May 27 '17 eng>rus mutations enhanсing ADCC functionality pro closed 1 no
May 27 '17 eng>rus ocular cells pro closed 1 no
May 26 '17 eng>rus incorporated fusions with IL-2 pro closed 1 no
May 26 '17 eng>rus antagonism or blocking functionality pro closed 1 no
May 26 '17 eng>rus fed batch overgrow pro closed 1 no
May 26 '17 eng>rus derived from the recombination pro closed 1 ok
May 23 '17 eng>rus nasal NK/T-cell lymphoma pro closed 2 no
May 23 '17 eng>rus reproduced herein as vs therein pro closed 2 no
May 23 '17 eng>rus has a Tscm-mediated disease pro closed 1 no
May 22 '17 eng>rus breakthrough GvHD occurs pro closed 1 no
May 22 '17 eng>rus at therapeutically effective frequency pro closed 2 no
May 22 '17 eng>rus adjunct to prophylaxis pro closed 1 no
May 22 '17 eng>rus pre-transplant conditioning regimen pro closed 1 no
May 21 '17 eng>rus clinical grading score pro closed 1 no
May 21 '17 eng>rus treated onset of the OX40L-mediated condition pro closed 1 no
May 21 '17 eng>rus improved prophylaxis pro closed 2 no
May 21 '17 eng>rus enables 80% stem cell donor chimerism pro closed 1 no
May 21 '17 eng>rus secukinumab pro closed 1 ok
May 20 '17 eng>rus optionally wherein pro closed 3 no
May 20 '17 eng>rus as defined in any one of aspects pro closed 1 no
May 20 '17 eng>rus thereby treated condition pro closed 2 no
May 20 '17 eng>rus grow in a distant focus pro closed 1 no
May 19 '17 eng>rus cell proliferative disorder pro closed 1 no
May 17 '17 eng>rus condition of choice pro closed 1 no
May 16 '17 eng>rus as part of the sequence identity pro closed 1 no
May 16 '17 eng>rus contingent on distant site pro closed 2 no
May 16 '17 eng>rus places in the body pro closed 2 no
May 16 '17 eng>rus abnormal vascular proliferation pro closed 1 no
May 16 '17 eng>rus FcRs to be identified in the future pro closed 1 no
May 15 '17 eng>rus single agent to be given pro closed 1 no
May 15 '17 eng>rus comparator antibody vs. comparator value pro closed 2 no
May 15 '17 eng>rus commercial packages of medicaments pro closed 1 no
May 14 '17 eng>rus cell being treated pro closed 2 no
May 14 '17 eng>rus palliating the disease state pro closed 1 no
May 14 '17 eng>rus prolonging survival of individuals pro closed 2 no
May 14 '17 eng>rus defer vs retard pro closed 2 no
May 14 '17 eng>rus desirably stop tumor metastas pro closed 1 no
May 13 '17 eng>rus As is understood in the clinical context pro closed 3 no
May 13 '17 eng>rus bovine, equine, canine, ovine (в патентах) pro closed 1 no
May 13 '17 eng>rus native source pro closed 2 no
May 13 '17 eng>rus recombinantly engineering pro closed 2 no
May 13 '17 eng>rus conserved from different species pro just_closed 0 no
May 12 '17 eng>rus measurable and reproducible interaction pro closed 2 no
May 10 '17 eng>rus fusion of an amino acid sequence pro closed 1 ok
May 9 '17 eng>rus include exclusive binding pro closed 1 no
May 9 '17 eng>rus randomly recruited pro closed 1 no
Asked | Open questions | Answered